ALLC
Probable inactive allantoicase
Also known as: ALC, ALLC_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8N6M5
- Gene
- ALLC
- Ensembl
- ENSG00000151360
- Chromosome
- 2
- Canonical length
- 391 aa
- Protein class
- Metabolic proteins, Predicted intracellular proteins
OverviewNCBI Gene
Allantoicase (EC 3.5.3.4) participates in the uric acid degradation pathway. Its enzymatic activity, like that of urate oxidase (MIM 191540), was lost during vertebrate evolution.[supplied by OMIM, Nov 2008]
Canonical amino-acid sequenceUniProt
391 residues, UniProt reviewed canonical sequence.
>Q8N6M5|ALLC
1 MDMASESVGG KILFATDDFF APAENLIKSD SPCFKEHEYT EFGKWMDGWE TRRKRIPGHD
61 WCVLRLGIQG VIRGFDVDVS YFTGDYAPRV SIQAANLEED KLPEIPERGT RTGAAATPEE
121 FEAIAELKSD DWSYLVPMTE LKPGNPASGH NYFLVNSQQR WTHIRLNIFP DGGIARLRVF
181 GTGQKDWTAT DPKEPADLVA IAFGGVCVGF SNAKFGHPNN IIGVGGAKSM ADGWETARRL
241 DRPPILENDE NGILLVPGCE WAVFRLAHPG VITRIEIDTK YFEGNAPDSC KVDGCILTTQ
301 EEEAVIRQKW ILPAHKWKPL LPVTKLSPNQ SHLFDSLTLE LQDVITHARL TIVPDGGVSR
361 LRLRGFPSSI CLLRPREKPM LKFSVSFKAN PLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ALLC can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 16 nTPM
Expression across tissuesHPA
Tissue
- testis: 16 nTPM
- gallbladder: 0.6 nTPM
- liver: 0.6 nTPM
- kidney: 0.4 nTPM
- ovary: 0.2 nTPM
- adrenal gland: 0.1 nTPM
Single-cell type
- early spermatids: 179 nCPM
- late primary spermatocytes: 93 nCPM
- late spermatids: 42 nCPM
- peritubular myoid cells: 17 nCPM
- proximal tubule cells: 14 nCPM
- undifferentiated spermatogonia: 4.5 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 2.1 nTPM
- basal ganglia: 0.5 nTPM
- amygdala: 0.3 nTPM
- cerebral cortex: 0.3 nTPM
- hypothalamus: 0.3 nTPM
- medulla oblongata: 0.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.48
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.2
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- allantoin catabolic process
Molecular functions
- allantoicase activity
Protein domainsUniProt · Pfam · InterPro
- Galactose-binding-like domain superfamily
- Allantoicase
- Allantoicase domain
- Allantoicase repeat
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ALLC as an antibody target. Whether an autoantibody or antibody against ALLC could matter depends on whether native ALLC is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ALLC is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ALLC as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...